Jim Cramer Says “I Should Have Pulled the Trigger on Regeneron”

Core Viewpoint - Regeneron Pharmaceuticals, Inc. is recognized as a strong investment opportunity, particularly in the pharmaceutical sector, with potential for continued growth despite recent market fluctuations [1][2]. Company Overview - Regeneron Pharmaceuticals specializes in medicines for various conditions, including eye diseases, immune disorders, cancer, cardiovascular issues, infections, and rare diseases [2]. Stock Performance - The stock has shown significant recovery, rising from its lows in summer 2025, and is currently priced at approximately $750 [2]. - The company has been noted for its quiet but impactful progress in the market, with management emphasizing the importance of staying focused on their developments [2]. Investment Sentiment - There is a recognition of missed opportunities in investing in Regeneron, indicating a strong belief in its potential compared to other pharmaceutical stocks [1][2]. - While Regeneron is viewed positively, some analysts suggest that certain AI stocks may offer greater upside potential with less risk [3].